您的位置: 首页 > 农业专利 > 详情页

BIOMARKERS FOR PREDICTING RESPONSE OF DLBCL TO TREATMENT WITH A BTK INHIBITOR
专利权人:
PHARMACYCLICS LLC
发明人:
SCHWEIGHOFER, KARL,ECKERT, KARL,KUO, HSU-PING,CHANG, BETTY,BEAUPRE, DARRIN,CHEUNG, LEO
申请号:
SG11201700774U
公开号:
SG11201700774UA
申请日:
2015.07.31
申请国别(地区):
SG
年份:
2017
代理人:
摘要:
Disclosed herein, are methods, systems, compositions, arrays, and kits for using biomarkers, biomarker genes (e.g. EP300, MLL2, BCL-2, RB1, LRP1B, PIM1, TSC2, TNFRSF11A, SMAD4, PAX5, CARD11, ACTG2, LOR, GAPT, CCND2, SELL, GEN1, HDAC9, CD79B, MYD88, and ROS1) or biomarker gene expression levels for stratifying a patient having a hematological malignancy such as DLBCL for treatment, and administering a TEC inhibitor to selected patients. Also disclosed herein are methods, systems, compositions, arrays, and kits for using biomarkers, biomarker genes, or biomarker gene expression levels for monitoring a patient during treatment of a hematological malignancy such as DLBCL or FL or for optimizing a treatment regimen with a TEC inhibitor.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充